Using a drug to prevent acute graft-versus-host disease in young patients after stem cell transplants
Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10847516
This study is looking at whether adding a medication called vorinostat can help prevent a condition called graft-versus-host disease (GVHD) in kids and young adults who are getting a special type of stem cell transplant, aiming to make the treatment safer and more effective.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10847516 on ClinicalTrials.gov |
What this research studies
This research investigates the use of vorinostat, a histone deacetylase inhibitor, to prevent acute graft-versus-host disease (GVHD) in children, adolescents, and young adults undergoing allogeneic hematopoietic cell transplantation. The study aims to enhance the safety and effectiveness of GVHD prophylaxis by combining vorinostat with standard treatments. Participants will be monitored for safety and efficacy, with a focus on reducing the incidence of GVHD while preserving the beneficial effects of the transplant. This approach builds on previous adult studies that showed promising results in preventing GVHD.
Who could benefit from this research
Good fit: Ideal candidates for this research are children, adolescents, and young adults who are scheduled to undergo allogeneic hematopoietic cell transplantation.
Not a fit: Patients who are not undergoing allogeneic hematopoietic cell transplantation or those with contraindications to vorinostat may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the occurrence of acute GVHD, improving the quality of life and health outcomes for young transplant recipients.
How similar studies have performed: Previous studies in adults have shown that vorinostat can be safe and may help prevent GVHD, indicating potential for success in pediatric populations.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHOI, SUNG WON — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: CHOI, SUNG WON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: disorder prevention, disease prevention